Is the Neurotechnology Market growing now?
In our neurotechnology market deck, you will find everything you need to understand the market
SUMMARY
Yes, the neurotechnology market is genuinely growing now. The strongest evidence comes from several things moving together: funding, commercial device revenue, human deployment, acquisitions, regulatory progress and reimbursement.
The market is much broader than implanted brain-computer interfaces. Today, most commercial neurotechnology still comes from neuromodulation, including deep-brain, spinal-cord, vagus-nerve and peripheral-nerve stimulation.
Funding accelerated sharply without a comparable jump in the number of financings. Neurotech Futures tracked capital rising from roughly $2.3 billion in 2024 to $4.8 billion in 2025 while deal count increased only 8.5%, meaning investors mainly wrote much larger checks.
That boom is concentrated. In Neurofounders' H1 2026 dataset, 13 financings of at least $50 million captured roughly three-quarters of disclosed capital, so a handful of companies account for a large part of the apparent market acceleration.
BCIs are becoming clinically real, but they are not yet a scaled commercial market. Neuralink, Precision Neuroscience and Synchron now have meaningful human experience, yet general-purpose implanted BCI patient counts remain tiny beside established neuromodulation platforms.
The clearest commercial evidence comes from existing neural-device businesses. Boston Scientific, LivaNova and NeuroPace collectively grew comparable quarterly neurotechnology revenue by about 12%, while Medtronic's much larger neuromodulation business also expanded.
Newer products are beginning to cross the gap from approval to actual purchasing. ONWARD Medical moved ARC-EX from US authorization to more than 80 rehabilitation clinics and €3.7 million of 2025 product revenue.
Large medtech buyers are treating neurotechnology as a strategic growth area. Medtronic paid $650 million upfront for SPR Therapeutics, while Boston Scientific agreed to acquire Nalu Medical at a valuation of roughly $600 million.
Not every neurotech business is winning. Nevro had more than $400 million of annual revenue before being acquired by Globus Medical for roughly $253 million, a reminder that installed base and technological sophistication do not guarantee healthy economics.
The market therefore has two speeds. Neuromodulation already supports multi-billion-dollar medical-device businesses, while BCIs are progressing faster in funding and clinical capability than in commercial revenue.
The key question is no longer whether neurotechnology can work in humans. It is whether the most ambitious systems can survive long clinical timelines, prove durable benefit, secure reimbursement and scale implantation without the capital market losing patience.
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
What exactly counts as the neurotechnology market?
The neurotechnology market we are assessing here includes technologies that directly read, stimulate or interface with the nervous system, from brain-computer interfaces to deep-brain stimulation, spinal-cord stimulation, peripheral nerve stimulation, EEG systems and specialized neural diagnostics.
That boundary changes the answer quite a lot. A definition limited to implanted brain-computer interfaces would leave us with an exciting but still tiny clinical market. At the other extreme, including CNS drugs, generic mental-health apps and every piece of neurological software would create a huge category that tells us very little about whether neurotechnology itself is taking off.
We use a definition close to the one used by Neurofounders in its industry database: neurotechnology needs to be central to the product, generally through measuring, modulating or interfacing with the nervous system. Conventional pharmaceuticals and generic digital-health products stay outside.
That gives us something concrete to test. We can look at how much money neurotech companies are raising, whether neural devices are selling more, how quickly experimental technologies are moving through human trials, and whether newly approved products are actually reaching customers.
Why does neurotechnology suddenly feel much bigger today?
Neurotechnology feels much bigger today because several parts of the market that used to move separately are now advancing at the same time.
Venture money is one reason. Neurotech Futures tracked roughly $2.3 billion of private investment in 2024 and $4.8 billion in 2025. Neurofounders then counted another $2.64 billion across 81 financing events in the first half of 2026 using a broader methodology that also includes debt, grants and some public financing.
Human BCI programs have moved forward too. Neuralink went from three implanted participants at the beginning of 2025 to 21 announced participants by early 2026. Precision Neuroscience now says its cortical interface has been used in more than 95 patients across more than 15 hospital partners.
Meanwhile, the less glamorous side of neurotechnology keeps selling more devices. Boston Scientific's latest neuromodulation revenue grew 12.7% year over year. LivaNova's grew 10.1%. NeuroPace's RNS epilepsy-device revenue grew 21.3%.
More capital, more human use and more commercial revenue are showing up together. A few years ago, the neurotech boom case leaned much more heavily on what might eventually happen. These days there is considerably more evidence of what is already happening.
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Is neurotech funding actually accelerating now?
Neurotech funding is accelerating hard in dollar terms, although the number of financings is rising much more slowly.
Neurotech Futures counted around $2.3 billion across 129 private deals in 2024. The same research project counted approximately $4.8 billion across 140 deals in 2025. Capital therefore increased about 109%, while deal count rose only 8.5%.
The rough amount invested per financing moved from about $17.8 million to $34.3 million in one year. Investors did not suddenly finance twice as many neurotech companies. They wrote much larger checks.
The upper end expanded especially quickly. Seven companies crossed $100 million of financing in the 2024 dataset. In 2025, 11 companies raised rounds of at least $100 million. Early rounds also became heavier: Neurotech Futures counted approximately $554 million across 24 Series A rounds in 2025, compared with $393 million across 27 rounds a year earlier.
The latest H1 review from Neurofounders points in the same direction. It counted $2.64 billion across 81 events. Because that dataset includes several types of financing beyond private equity, we should not compare it directly with the Neurotech Futures annual figures. What we can say confidently is that the flow of capital has remained unusually large.
| Period | Capital tracked | Financing events | What we see |
|---|---|---|---|
| 2024 | ~$2.3B | 129 | Strong baseline year |
| 2025 | ~$4.8B | 140 | Dollars +109%, deals +8.5% |
| H1 2026 | ~$2.64B | 81 | Funding remains very high, using a broader methodology |
If you want more recent data on this point, please see our latest neurotechnology market report.
Is the neurotech funding boom spread across the market?
No. Neurotech funding is still highly concentrated, and that makes the boom look broader than it really is.
Neurofounders currently tracks 363 neurotechnology startups. Only around 22% recorded a financing event during the first half of 2026. More than half of disclosed rounds were below $10 million, and the median disclosed round was about $7.9 million.
At the top, the picture is almost reversed. Thirteen financings of at least $50 million captured roughly three-quarters of all disclosed capital.
BCI shows this concentration clearly. Science Corporation raised $230 million and Merge Labs raised $252 million. Those two deals alone represented around 70% of the BCI money Neurofounders tracked in the first half.
Consumer neurotech was even more concentrated. BrainCo raised roughly $286 million and Temple another $54 million. Together they represented about 95% of the category's approximately $357 million total. Remove those two financings and the supposedly hot consumer-neurotech category shrinks to less than $20 million of funding in the dataset.
At the other end, diagnostics and assessment attracted only about $48 million during the same period. Neuroimaging reached roughly $125 million.
Neuromodulation looks healthier underneath the headline. Around $791 million went into the category, spread among companies including Cognito Therapeutics, Spiro Medical, Nervonik, Nyxoah, ONWARD Medical, Cala Health and Neuros Medical.
Investors are clearly putting much more money into neurotechnology, but access to that money is far from universal. Right now, a relatively small group of companies is taking a very large share of the capital.
This chart, featured in our neurotechnology market deck, shows annual VC investment in neurotechnology startups
Are brain-computer interfaces actually becoming a real market?
Brain-computer interfaces are becoming a real clinical field now, but commercially they are still much closer to an emerging medical-device category than a scaled market.
The amount of money going into BCIs can make the category look more mature than it is. Neuralink raised $650 million in 2025. Synchron raised $200 million later that year. Science Corporation raised another $230 million this year, while Merge Labs came out with a $252 million round.
Those are enormous financings for companies whose core technologies are still going through clinical development.
Neuralink's progress is real. Its Telepathy program has reached 21 participants, and the company says some users have achieved cursor-control information-transfer rates around or above those of an able-bodied person using a mouse. Participants are using the interface for computers, phones and robotic arms rather than only performing short laboratory tasks.
Precision Neuroscience provides another useful benchmark. The company currently reports more than 95 implanted clinical-study patients and more than 15 active hospital partners. Its Layer 7 cortical interface has FDA clearance for temporary use, although its intended fully implanted wireless BCI remains under development.
Synchron is further evidence that the field has moved beyond a handful of academic experiments. Its Stentrode system had reached 10 implanted paralysis patients when the company raised its $200 million Series D, with the money intended partly for pivotal trials and preparations for commercialization.
BCIs are clinically real. They are not commercially mature. The technical question has shifted from whether humans can use these systems at all toward whether companies can implant them repeatedly, prove durable benefit and turn them into approved products.
If you want more recent data on this point, please see our latest neurotechnology market report.
Are BCI trials finally moving beyond impressive demos?
Yes, BCI trials are moving beyond one-off demonstrations, although patient numbers are still tiny compared with established neurotechnology.
Neuralink gives us a clean view of the acceleration. The company implanted one participant in the first half of 2024, two in the second half, four in the first half of 2025 and 13 in the second half of 2025. It went from a historic first implant to multiple procedures per month.
The quality of use is changing as well. Neuralink reports participants using Telepathy for everyday computer control, education, creative work and robotic-arm operation. One participant has used the interface for periods of up to 17 hours a day, according to the company's latest clinical update. Neuralink has also started a speech-focused study and lists a vision-restoration study as upcoming.
Precision Neuroscience has taken another route, using a cortical array that can temporarily sit on the brain surface during clinical procedures. Its 95-plus patient count gives the company a much larger pool of human neural recordings than the headline implanted-BCI numbers alone would suggest.
Still, the scale gap is huge. Established deep-brain-stimulation platforms already treat populations measured in tens of thousands. General-purpose implanted BCIs remain measured in tens.
For investors, that is enough progress to make BCI commercialization a serious question today. For anyone claiming mass adoption has started, the numbers remain far too small.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Is neuromodulation actually the biggest neurotech business today?
Yes, neuromodulation is currently the economic core of neurotechnology, even though BCIs receive far more attention.
Medtronic generated $2.068 billion of neuromodulation revenue in its latest fiscal year, up 7% from $1.932 billion. Boston Scientific's neuromodulation division is now running above $300 million of quarterly sales. LivaNova's business produces more than $150 million per quarter, mostly from vagus-nerve stimulation. NeuroPace is much smaller but is approaching a $100 million annual revenue run rate around its responsive neurostimulation platform.
These are already real medical-device businesses with physicians, reimbursement, implanted patient bases and recurring replacement or follow-on demand.
Their products also show how far neurotechnology has moved beyond simple electrical stimulation. Medtronic's adaptive deep-brain-stimulation system reads a patient's brain signals and adjusts stimulation in response. NeuroPace's RNS system records abnormal neural activity and responds with stimulation. Modern neuromodulation is becoming increasingly closed-loop.
Hospitals already implant electronics that sense and alter nervous-system activity at meaningful scale. BCIs are trying to push that model into much more ambitious functions such as computer control, speech and vision. For now, though, neuromodulation pays most of the bills.
If you want more recent data on this point, please see our latest neurotechnology market report.
Are neurotechnology companies growing revenue right now?
Yes, several established neurotechnology businesses are growing at double-digit rates right now, which gives us unusually clean evidence of actual market expansion.
Boston Scientific reported $341 million of neuromodulation sales in its latest quarter, compared with $303 million a year earlier, an increase of 12.7%. LivaNova reported $166.9 million, up 10.1% from $151.7 million. NeuroPace's RNS revenue reached $22.5 million, up 21.3%.
If we combine those three businesses ourselves, quarterly revenue increased from roughly $473 million to $530 million. That is about 12.1% year-over-year growth across more than half a billion dollars of quarterly sales.
Medtronic gives us a slower but much larger reference point. Its neuromodulation revenue reached $2.068 billion in its latest fiscal year, growing 7% on a reported basis and 5.2% organically.
The companies are also growing for somewhat different reasons. LivaNova said its latest neuromodulation increase came from higher volumes and pricing across all regions. NeuroPace is adding prescribers and accounts around epilepsy treatment. Boston Scientific operates across spinal-cord and other stimulation therapies.
Several independent businesses growing simultaneously is much stronger evidence than one startup reporting a good launch.
| Neurotechnology business | Latest revenue | Comparable prior period | Growth |
|---|---|---|---|
| Boston Scientific neuromodulation | $341.0M quarterly | $303.0M | +12.7% |
| LivaNova neuromodulation | $166.9M quarterly | $151.7M | +10.1% |
| NeuroPace RNS | $22.5M quarterly | ~$18.6M | +21.3% |
| Three-company basket | $530.4M quarterly | ~$473.3M | +12.1% |
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
Are new neurotech products actually finding paying customers?
Some new neurotechnology products are already finding paying customers, and ONWARD Medical gives us one of the cleanest examples of that transition.
ONWARD received US authorization for its ARC-EX non-invasive spinal-cord-stimulation system in late 2024. During 2025, ARC-EX product revenue reached €3.7 million, up from only about €80,000 the previous year.
By year-end, more than 80 US rehabilitation clinics had purchased at least one ARC-EX system. ONWARD estimated that this represented roughly 25% of the approximately 300 specialized rehabilitation clinics it initially targeted in the country. By early March, the number of active non-VA clinics had reached 86, or roughly 29% of that addressable clinic base.
The company is still small and loss-making. Its 2025 operating loss was €40.9 million, much larger than product revenue. Yet that makes the commercial progress easier to read. We can see a neurotechnology product going from regulatory authorization to dozens of clinics and millions of euros in sales without pretending the company has already reached scale.
Other parts of the market are following the same commercialization ladder. Recent Neurofounders tracking found FDA clearances for Universal Brain and Zeta Surgical, European regulatory milestones for Newronika and Time is Brain, a Medicare reimbursement improvement for Neuspera and insurance coverage for Theranica extending beyond half of the US insured population.
Approval by itself does not create a market. Reimbursement, physician adoption and repeat purchases do. More neurotech companies are now reaching those stages.
Are big medtech companies putting serious money into neurotechnology?
Yes, large medtech companies are spending hundreds of millions of dollars to expand in neurotechnology, especially around peripheral nerve stimulation and neuromodulation.
Medtronic completed its acquisition of SPR Therapeutics in July for $650 million upfront. SPR's SPRINT system provides temporary peripheral nerve stimulation for pain, giving Medtronic another way to treat patients earlier in the pain-care pathway.
Boston Scientific recently completed its acquisition of Nalu Medical after agreeing to value the whole company at roughly $600 million. Nalu's peripheral nerve stimulation system generated more than $60 million of expected 2025 sales, and Boston Scientific expected revenue growth above 25% in 2026 when it announced the transaction.
Two large medtech companies therefore committed about $1.25 billion to peripheral nerve stimulation businesses within a relatively short period. That repeated buyer behavior tells us more than either acquisition alone.
There is a useful counterexample. Globus Medical bought Nevro for roughly $253 million even though Nevro had been generating more than $400 million of annual revenue. Nevro had struggled with declining sales and losses, so its technology did not protect shareholders from a severe loss of value.
The acquisition market is showing a clear preference: buyers want neurotechnology, but they will pay much more for businesses that still have growth ahead of them.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Are regulation and reimbursement getting easier for neurotech companies?
Regulation and reimbursement are becoming more supportive in several neurotechnology niches, although they remain major bottlenecks for the most invasive products.
The recent flow of approvals is wider than one company. Neurofounders' latest commercialization tracking highlighted FDA clearances for Universal Brain and Zeta Surgical, European marks for Newronika and Time is Brain, Medicare parity for Neuspera and broader US insurance coverage for Theranica.
China is moving quickly too. Neuracle's NEO-ONE SCI became the country's first approved implantable brain interface earlier this year, according to Neurofounders' review of the Chinese market. Neuracle subsequently began preparing for an IPO, while Chinese industry sources counted 34 BCI financing events during the first half of 2026.
At the same time, approval still means very different things across neurotechnology. Precision Neuroscience's FDA-cleared Layer 7 interface can be used temporarily for less than 30 days. Its fully implantable BCI remains in development. Synchron is preparing for larger pivotal work. Neuralink remains in clinical trials.
Lower-risk and already familiar forms of neurotechnology can move into commercial use relatively quickly. Permanent brain implants still face a much longer test around safety, durability, surgery and clinical benefit.
That gap is one reason neuromodulation can grow commercially today while ambitious BCIs remain mostly a venture-funded clinical story.
What could still stop the neurotechnology market from growing much faster?
The biggest risk to neurotechnology growth is that the most heavily funded companies take much longer than investors expect to turn impressive human results into scalable products.
BCIs illustrate the problem. A system can decode a cursor extremely well in 20 people and still be years away from becoming a large medical-device business. Scaling requires reliable surgery, manufacturing, long-term implant durability, regulatory approval, physician training, reimbursement and enough patient benefit to justify an invasive procedure.
Capital concentration adds another vulnerability. Neurofounders found that only around 22% of its tracked startups raised money during the first half of 2026, while 13 large financings captured roughly three-quarters of disclosed capital. If investors become less willing to finance long clinical timelines, many smaller neurotech companies could feel the downturn even while a few leaders remain well funded.
The Nevro acquisition shows that commercial neurotechnology can struggle too. Nevro entered 2025 with annual revenue above $400 million, yet Globus Medical acquired it for only about $253 million. A large installed base does not guarantee healthy growth or a high valuation.
Timelines also vary wildly inside the same market. ONWARD could start selling its non-invasive ARC-EX system soon after authorization. Medtronic can add new stimulation products to an existing sales network. An implanted BCI designed to restore speech has to clear a much higher bar.
We are confident that neurotechnology is growing today. We are much less confident that every part of the market will grow at anything close to the pace implied by venture valuations.
This chart, featured in our neurotechnology market deck, breaks down revenue by customer segment in the neurotechnology market
Is the neurotechnology market growing now?
Yes, the neurotechnology market is genuinely growing now, and the evidence is broad enough that we no longer have to rely mainly on futuristic BCI promises.
Private neurotech investment roughly doubled from $2.3 billion in 2024 to $4.8 billion in 2025, even though deal count increased only slightly. The latest H1 funding data remains very strong. At the same time, Boston Scientific, LivaNova and NeuroPace collectively grew comparable quarterly neural-device revenue by about 12%.
Commercialization is spreading too. ONWARD has moved from authorization into dozens of US clinics. Medtronic just spent $650 million acquiring SPR Therapeutics. Boston Scientific bought Nalu after the company built a business expected to exceed $60 million of annual sales. Recent regulatory and reimbursement wins are opening additional routes to market.
BCIs sit at a much earlier point. Neuralink, Precision Neuroscience and Synchron have moved human neural interfaces well beyond isolated demonstrations, but their patient populations are still small. Huge funding rounds are arriving years before we can confidently estimate what general-purpose implanted BCI revenue will look like.
The market has two very different speeds. Neuromodulation is already a multi-billion-dollar medical-device business and is currently growing at healthy single- to double-digit rates. BCIs are advancing much faster clinically and financially than commercially.
Our answer is still a clear yes. Neurotechnology is growing now in funding, revenue, clinical deployment, acquisitions and regulatory progress. The part worth resisting is the idea that the whole market has suddenly reached BCI-driven mass adoption. Today, most of the real money still comes from technologies that stimulate the nervous system for specific medical problems, while next-generation BCIs are building the case that they could become the next major layer of the market.
If you want more recent data on this point, please see our latest neurotechnology market report.
OUR METHODOLOGY
This analysis tests whether the neurotechnology market is genuinely growing now by separating capital-market excitement from commercial and clinical progress. We look at capital formation, commercial revenue, clinical deployment, product adoption, strategic acquisitions, and regulatory and reimbursement progress rather than relying on a single market-size forecast.
We define neurotechnology as technology in which measuring, modulating or interfacing with the nervous system is central to the product. That includes brain-computer interfaces, deep-brain stimulation, spinal-cord stimulation, peripheral nerve stimulation, EEG systems and specialized neural diagnostics. Conventional CNS pharmaceuticals, generic mental-health apps and broad neurological software sit outside the market for this analysis.
Funding figures are treated carefully because the underlying datasets are not identical. Neurotech Futures is used for the 2024 and 2025 private-investment trend, while Neurofounders' H1 2026 review uses a broader methodology that can include debt, grants and some public financing. We use those datasets to show direction and concentration rather than treating them as one continuous series.
Commercial growth is anchored in reported company revenue, particularly neuromodulation results from Boston Scientific, LivaNova, NeuroPace and Medtronic. Clinical maturity is assessed separately through participant counts, hospital use and regulatory status at Neuralink, Precision Neuroscience and Synchron. That separation is important because BCIs can advance quickly in human trials while remaining far smaller commercially than established neuromodulation.
Product adoption and strategic activity are used as additional tests of whether the market is moving beyond research. ONWARD Medical provides a useful commercialization example through ARC-EX clinic adoption and product revenue, while Medtronic's acquisition of SPR Therapeutics, Boston Scientific's acquisition of Nalu Medical and Globus Medical's acquisition of Nevro show how large medtech buyers are valuing different neurotechnology businesses.
Key sources used for this analysis include: Neurofounders' H1 2026 funding review, Neuralink's Two Years of Telepathy update, Precision Neuroscience, the FDA record for Precision's Layer 7-T clearance, Synchron's company news, LivaNova's Q2 2026 results, NeuroPace's Q2 2026 results, Boston Scientific's 2026 quarterly results, ONWARD Medical's 2025 annual report, Medtronic on the SPR Therapeutics acquisition, Boston Scientific on the Nalu Medical acquisition, and Globus Medical's filing covering the Nevro acquisition.
This chart, featured in our neurotechnology market deck, shows how brain sensing wearable technology has evolved over time
Related blog posts
